XML 46 R30.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration Revenues | The following table summarizes the amounts recorded in the consolidated statements of income for each significant collaboration for the three months ended March 31, 2015 and 2014.
| Three Months Ended March 31, 2015
| Collaboration Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 644 |  |  | $ | 3,157 |  |  | $ | 3,801 |
Oragenics, Inc. | 262 |  |  | 8 |  |  | 270 |
Fibrocell Science, Inc. | 448 |  |  | 1,713 |  |  | 2,161 |
Genopaver, LLC | 69 |  |  | 600 |  |  | 669 |
S & I Ophthalmic, LLC | — |  |  | 755 |  |  | 755 |
OvaXon, LLC | — |  |  | 644 |  |  | 644 |
Intrexon Energy Partners, LLC | 625 |  |  | 2,185 |  |  | 2,810 |
Persea Bio, LLC | 125 |  |  | 115 |  |  | 240 |
Other | 858 |  |  | 2,527 |  |  | 3,385 |
Total | $ | 3,031 |  |  | $ | 11,704 |  |  | $ | 14,735 |
| Three Months Ended March 31, 2014
| Collaboration Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 644 |  |  | $ | 2,036 |  |  | $ | 2,680 |
Oragenics, Inc. | 262 |  |  | 533 |  |  | 795 |
Fibrocell Science, Inc. | 448 |  |  | 862 |  |  | 1,310 |
Genopaver, LLC | 69 |  |  | 421 |  |  | 490 |
S & I Ophthalmic, LLC | — |  |  | 879 |  |  | 879 |
OvaXon, LLC | — |  |  | 169 |  |  | 169 |
Other | 459 |  |  | 1,055 |  |  | 1,514 |
Total | $ | 1,882 |  |  | $ | 5,955 |  |  | $ | 7,837 |
Summary of Deferred Revenue | Deferred revenue consists of the following:
| March 31, 2015 |  | December 31, 2014
Upfront and milestone payments | $ | 104,297 |  |  | $ | 107,228 |
Prepaid research and development services | 1,038 |  |  | 1,045 |
Prepaid product and service revenues | 4,740 |  |  | 4,365 |
Other | 1,212 |  |  | 571 |
Total | $ | 111,287 |  |  | $ | 113,209 |
Current portion of deferred revenue | $ | 17,289 |  |  | $ | 16,522 |
Long-term portion of deferred revenue | 93,998 |  |  | 96,687 |
Total | $ | 111,287 |  |  | $ | 113,209 |

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and aggregated nonsignificant collaborations. + References No definition available. + Details
Name: | xon_CollaborationRevenuesTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration